TotalMarketCap

Novavax

NVAXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.609 B

$9.76 -8.40%

Close of 6 Nov 2026

As of 6 Nov 2026, Novavax (NVAX) has a market capitalization of $1.61B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.12B

#1453 by revenue

Earnings

$440.3M

#668 by earnings

Shares outstanding

165,009,009

Latest filing cover page

P/E ratio

3.7

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #38Maze TherapeuticsMAZE$1.80B
  2. #39AlvotechALVO$1.78B
  3. #40NovavaxNVAX$1.61B
  4. #41Lycia TherapeuticsLYCA$1.50B
  5. #42ImmunocoreIMCR$1.47B

What if Novavax were worth as much as…

Open the what-if tool →

Gold $28.2T

$171,188.88

Per share 17,549× higher

Bitcoin $1.53T

$9,262.73

Per share 950× higher

Apple $5.02T

$30,408.68

Per share 3,117× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Novavax are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.